The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
According to the 2022 European LeukemiaNet, all acute myeloid leukemia (AML) cases with FLT3‐ITD mutations are now categorized as intermediate risk irrespective of the FLT3‐ITD allelic ratio or concurrent presence of NPM1 mutation. However, whether other next‐generation sequencing (NGS) comutation genes can add layers to FLT3‐ITD and whether the poor outcomes of FLT3‐ITD comutations can be overcome...
Acute myeloid leukaemia (AML) patients with biallelic mutations of CEBPA (bi CEBPA) have a 30–50% relapse rate. This study established the value of mutations based on next‐generation sequencing (NGS) and multiparameter flow cytometric measurable residual disease (MFC‐MRD) detection and compared the outcomes. From 2014 to 2018, 124 newly diagnosed bi CEBPA AML patients were treated. The median age...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.